$92.00
▲ +1.2% Today
as of Jul 22, 16:47 ET
Last 30 days
Recent Press Releases & News
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
CORT: Raising target price to $100.00
Corcept's CFO Set His Selling Plan the Month the Stock Fell 50% — Here's What Investors Should Know
Overview
52-week range
$29
$91
100% of range
Avg surprise (last 2)
+13.0%
Avg reaction (last 1)
+1.6%
100% positive
Latest IV / EM
66%
EM ±15.1% · $90 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Mar 31, 2026 | Mar 2026 | $-0.30 | — | — | — | — | financials |
| Tue Sep 30, 2025 | Sep 2025 | $0.16 | — | — | — | — | financials |
| Thu Jul 31, 2025 | Jun/2025 | $0.29 | $0.23 | +26.1% | — | — | earnings |
| Mon May 5, 2025 | Mar/2025 | $0.17 | $0.17 | 0.0% | — | +1.6% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $0.41 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $0.32 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $0.25 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $0.28 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $0.25 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Jul 30, 2026 | Jun/2026 | OTHER | -$0.04 | $0.29 | -113.8% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $165M | — | $208M | $194M | $157M | — | $183M | $164M |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-50M | — | $10M | $27M | $3M | — | $47M | $36M |
| Net income | $-32M | — | $20M | $35M | $21M | — | $47M | $35M |
| EPS (diluted) | $-0.30 | — | $0.16 | $0.29 | $0.17 | — | $0.41 | $0.32 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $109M | $120M | $125M | $103M | $90M | $128M | $137M | $129M |
| Inventory | $13M | $13M | $12M | $12M | $14M | $12M | $8M | $8M |
| Total current assets | $426M | $485M | $541M | $443M | $439M | $472M | $467M | $561M |
| Total assets | $815M | $837M | $824M | $802M | $846M | $841M | $784M | $715M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $177M | $189M | $192M | $166M | $163M | $161M | $145M | $118M |
| Total equity | $638M | $648M | $632M | $636M | $683M | $680M | $639M | $596M |